Solana (NASDAQ:HSDT) Issues Earnings Results, Misses Estimates By $0.03 EPS

Key Points

• Quarterly results missed expectations: Solana reported a loss of $0.05 per share versus the expected $0.02 loss, while revenue of $2.53 million fell short of the $3.50 million consensus.
• Staking operations expanded: The company generated $2.5 million in second-quarter staking revenue, launched its first institutional validator cluster in Tokyo with roughly 500,000 SOL committed, and expects validator-related revenue to begin in the third quarter.
• Losses and financial risks remained significant: GAAP net loss reached $30.3 million, including $25.4 million in realized digital-asset losses, while cash stood at $3.6 million; shares fell 5.6% to $1.70.

Solana (NASDAQ:HSDT - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.03), Zacks reports. The company had revenue of $2.53 million for the quarter, compared to analysts' expectations of $3.50 million. Solana had a negative return on equity of 67.57% and a negative net margin of 1,427.15%.

Here are the key takeaways from Solana's conference call:

• Institutional infrastructure launched: Solana Company’s first validated cluster is operational in Tokyo, with approximately 500,000 SOL in committed third-party stake and validator-related revenue expected to begin in the third quarter.
• Staking performance remained strong: The company generated $2.5 million, or 31,200 SOL, in second-quarter staking revenue and achieved a 6.14% net annualized yield versus a network average of approximately 5.68%.
• Legacy-business transition advanced: The cash-consuming medical-device business was divested, while the company completed its acquisition of a Hong Kong regulated trust company on July 15 for $2 million to support its Asia-Pacific institutional strategy.
• GAAP losses remained substantial: The company reported a $30.3 million second-quarter net loss, including a $25.4 million realized loss on digital assets, while general and administrative expenses rose to $11.1 million, although management expects costs to decline as divestiture-related expenses end.
• Capital allocation will remain valuation-dependent: Solana Company repurchased $2.3 million of shares during the quarter while trading below net asset value, but management said future buybacks, SOL purchases, or business investment will depend on which option offers the greatest SOL-per-share accretion.

Solana Stock Down 5.6%

NASDAQ:HSDT traded down $0.10 on Friday, reaching $1.70. The company's stock had a trading volume of 137,150 shares, compared to its average volume of 106,755. Solana has a 12-month low of $1.19 and a 12-month high of $25.50. The stock has a 50 day moving average price of $1.67 and a 200 day moving average price of $1.95. The firm has a market cap of $99.26 million, a price-to-earnings ratio of -0.02 and a beta of 1.01.

Solana News Summary

Here are the key news stories impacting Solana this week:

• Positive Sentiment: Management expects to receive its first validator-related rewards in the third quarter of 2026. The company has committed approximately 500,000 SOL to support its Tokyo validator cluster, potentially creating a new recurring revenue stream. Solana Company expects first validator-related rewards in Q3 2026
• Positive Sentiment: Second-quarter revenue rose to approximately $2.5 million from $43,000 a year earlier, primarily from staking. Solana Company also earned 31,200 SOL in staking rewards, completed its Tokyo institutional validator cluster, expanded in Asia-Pacific, and divested its legacy PoNS medical-device business. Solana Company Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company generated $7.9 million from a registered direct offering and repurchased approximately $2.3 million of shares during the quarter, retiring 1.3 million shares. Its partnership with the Jito Foundation and expansion across Asia-Pacific could support future institutional demand.
• Neutral Sentiment: Recent institutional activity was mixed: 17 investors added HSDT shares while 21 reduced positions in their latest reported quarters. BlackRock increased its position, but several other funds fully exited or substantially cut holdings. Solana Co insider and institutional activity
• Negative Sentiment: Quarterly results missed expectations. Revenue of about $2.53 million was below the $3.50 million consensus estimate, while reported adjusted EPS of negative $0.05 missed the expected negative $0.02. Solana Company Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: GAAP net loss widened to $30.3 million, driven partly by $25.4 million of realized digital-asset losses and sharply higher expenses. General and administrative costs reached $11.1 million, cash was only $3.6 million at quarter-end, and the accumulated deficit rose to $342.6 million.
• Negative Sentiment: Wall Street Zen downgraded HSDT to “Sell,” adding to investor caution around the company’s substantial losses, liquidity needs, and exposure to SOL price volatility. Wall Street Zen downgrades Solana Company

Analyst Ratings Changes

HSDT has been the topic of several analyst reports. Zacks Research upgraded Solana to a "hold" rating in a report on Monday, April 27th. B. Riley Financial initiated coverage on shares of Solana in a research report on Thursday, April 23rd. They set a "buy" rating and a $3.00 price objective for the company. Wall Street Zen cut shares of Solana from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Solana in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Solana currently has a consensus rating of "Moderate Buy" and an average target price of $3.50.

Hedge Funds Weigh In On Solana

Hedge funds have recently modified their holdings of the business. Cetera Investment Advisers purchased a new stake in Solana in the 4th quarter valued at about $347,000. Price T Rowe Associates Inc. MD purchased a new position in Solana during the fourth quarter worth about $46,000. Geode Capital Management LLC purchased a new position in Solana during the fourth quarter worth about $1,006,000. LPL Financial LLC boosted its stake in Solana by 120.1% during the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company's stock worth $1,105,000 after buying an additional 208,558 shares during the period. Finally, State Street Corp acquired a new stake in shares of Solana during the fourth quarter valued at about $464,000. 18.63% of the stock is currently owned by hedge funds and other institutional investors.

Solana Company Profile

Helius Medical Technologies, Inc NASDAQ: HSDT is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source